Mortality following pituitary radiotherapy

Area of Science:

• Endocrinology
• Neurology
• Radiation Oncology

Background:

• External beam radiotherapy (EBRT) has been a long-standing treatment for pituitary adenomas, aiming to prevent tumor regrowth and manage hormonal hypersecretion.
• Despite its efficacy, EBRT is associated with serious complications, including secondary tumors, cognitive deficits, hypopituitarism, and cerebrovascular disease.

Purpose of the Study:

• To review the established benefits and significant risks associated with external beam radiotherapy in managing pituitary adenomas.
• To highlight the potential long-term adverse effects, such as hypopituitarism and cerebrovascular complications, and their impact on patient mortality.

Main Methods:

• Literature review of studies investigating the outcomes of external beam radiotherapy for pituitary adenomas.
• Analysis of reported complications, including secondary intracranial tumors, cognitive impairment, hypopituitarism, and cerebrovascular events.
• Examination of mortality data in patients treated with pituitary radiotherapy.

Main Results:

• EBRT is effective in controlling pituitary adenomas but carries substantial risks.
• Over 50% of patients develop hormone deficiencies within ten years post-radiotherapy.
• Cerebrovascular complications and increased mortality, particularly from cardiovascular and cerebrovascular disease, are noted concerns.

Conclusions:

• The long-term use of external beam radiotherapy for pituitary adenomas necessitates a thorough risk-benefit assessment for each patient.
• Further research is needed to clarify the direct causal links between pituitary radiotherapy and increased mortality.
• Alternative or refined radiotherapy techniques may be required to mitigate treatment-related morbidities.